{
    "clinical_study": {
        "@rank": "55335", 
        "arm_group": [
            {
                "arm_group_label": "YH16410", 
                "arm_group_type": "Experimental", 
                "description": "PO, Once Daily, 8 weeks"
            }, 
            {
                "arm_group_label": "Rosuvastatin", 
                "arm_group_type": "Active Comparator", 
                "description": "PO, Once Daily, 8 weeks"
            }, 
            {
                "arm_group_label": "Telmisartan", 
                "arm_group_type": "Active Comparator", 
                "description": "PO, Once Daily, 8 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "PO, Once Daily, 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate efficacy and safety of YH16410 versus rosuvastatin and telmisartan monotherapies\n      in patients with hypertension and hyperlipidemia"
        }, 
        "brief_title": "Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia", 
        "condition": [
            "Hyperlipidemia", 
            "Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed Informed Consent\n\n          -  Men and women \u2265 19 years of age\n\n          -  Subject who has one of 3 conditions classified by Cardiovascular Risk Factors,\n             10-Year Risk, Blood Pressure, LDL-C, TG, Coronary Artery Disease and Equivalent\n\n        Exclusion Criteria:\n\n          -  Females who are pregnant, breastfeeding, or of childbearing potential, unwilling to\n             practice adequate contraception throughout the study.\n\n          -  Other exclusions applied"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "190", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01914432", 
            "org_study_id": "YH16410-301"
        }, 
        "intervention": [
            {
                "arm_group_label": "YH16410", 
                "intervention_name": "YH16410", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rosuvastatin", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Telmisartan", 
                "intervention_name": "Telmisartan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Rosuvastatin", 
                    "Telmisartan", 
                    "Placebo"
                ], 
                "intervention_name": "YH16410 placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "YH16410", 
                    "Telmisartan", 
                    "Placebo"
                ], 
                "intervention_name": "Rosuvastatin placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "YH16410", 
                    "Rosuvastatin", 
                    "Placebo"
                ], 
                "intervention_name": "Telmisartan placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Telmisartan", 
                "Rosuvastatin", 
                "Benzoates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Investigate the Safety and Efficacy Between YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia", 
        "overall_official": {
            "affiliation": "Yuhan Corporation", 
            "last_name": "Su Youn Nam, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Diastolic Blood Pressure, Change in LDL Cholesterol", 
            "safety_issue": "Yes", 
            "time_frame": "Change from Baseline at 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01914432"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}